KRT1 and Liver abscess: As an alternative to treatment with antibiotics, monoclonal antibodies against the K1 CPS of K. pneumoniae can enhance phagocytosis to combat invasion of the bacterium and protected mice from K. pneumoniae-induced liver abscess and lethality [4], suggesting that the K1 CPS is a promising target for vaccine development against K. pneumoniae infection [5].